|drug819||Coala Heart Monitor Wiki||1.00|
There is one clinical trial.
The principal objective of the study is to determine if patient-empowered, real-time and home- based patient monitoring of vital parameters can lead to: - Reduction in admission rates and improved clinical management of chronically ill patients - Reduction in use of medications - Reported quality of life A minimum of 100 patients will be recruited, monitored and observed over 6 months from home with the Coala Heart Monitor. The study population will be representative of rural, high-risk, Medicare (65+ of age) subjects with chronic conditions and will be recruited by the Perry Community Hospital in Linden, TN.
Description: As measured by Rand-36Measure: Increased quality of life Time: 6 months
Description: The cloud-based Coala Care platform enables patient data to be shared and accessed efficiently with affiliated specialists. Show how this helps improve clinical management and healthcare processes.Measure: Show the value of using Coala Heart Monitor in rural care - providers Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports